18 F-PSMA PET/CT Versus 18 F-NaF PET/CT for Staging and Treating Newly Diagnosed High-Risk Prostate Cancer: A Prospective Single-Center Study
Journal of Nuclear Medicine · 2025
DOI: 10.2967/jnumed.125.270822 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Nuclear Medicine, 2025. Verfasst von Claus Madsen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Copenhagen University Hospital Herlev and Gentofte, Herlev, Denmark; claus.madsen@regionh.dk. Hauptthemen laut MEDLINE: Positron Emission Tomography Computed Tomography, Prostatic Neoplasms, Fluorine Radioisotopes, Sodium Fluoride. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Radiolabeled prostate-specific membrane antigen (PSMA) PET/CT has demonstrated superior diagnostic accuracy for staging prostate cancer (PC) compared with conventional imaging modalities. However, the clinical impact of replacing 18F-NaF PET/CT with PSMA PET/CT in high-risk PC remains underexplored.
Methods
In this prospective single-center study, 160 patients with newly diagnosed high-risk PC underwent both 18F-NaF PET/CT and 18F-PSMA-1007 PET/CT within 3 wk. The 18F-PSMA PET/CT results were initially withheld; therefore, staging and treatment decisions were based solely on 18F-NaF PET/CT. At a later time point, the 18F-PSMA PET/CT findings were revealed, and staging and treatment plans were reassessed in a multidisciplinary research setting. Differences in staging and treatment intent were analyzed using Wilcoxon signed-rank tests.
Results
The metastatic stage was reclassified for 40 patients (25%) after 18F-PSMA PET/CT, with 24% classified as having a more advanced stage and 1% having a less advanced stage (P < 0.001). Lymph node metastases accounted for most changes: 30 patients (19%) with no nodal involvement on CT were found to have nodal disease on 18F-PSMA PET/CT, and the rate of extrapelvic lymph node metastases increased from 16% to 27%. Treatment plans were changed for 21 patients (13%), primarily reflecting a shift from curative to noncurative intent or toward more intensified systemic therapy (P = 0.001).
Conclusion
The use of 18F-PSMA PET/CT resulted in significant metastatic stage migration and influenced treatment planning in a substantial proportion of patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Copenhagen University Hospital Herlev and Gentofte, Herlev, Denmark; claus.madsen@regionh.dk.
- Department of Nuclear Medicine and Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark.
- Department of Clinical Medicine, Aalborg University, Aalborg, Denmark.
- Department of Nuclear Medicine, Copenhagen University Hospital Herlev and Gentofte, Herlev, Denmark.
- Department of Radiology, Copenhagen University Hospital Herlev and Gentofte, Herlev, Denmark.
- Department of Clinical Medicine, Copenhagen University, Copenhagen, Denmark.
Zitieren
APA
Madsen, C., Zacho, H. D., Fuglø, D., Nielsen, K., Kongsted, P., Bisbjerg, R., Pedersen, M., Broholm, R., Haarmark, C., & Østergren, P. B. (2025). 18 F-PSMA PET/CT Versus 18 F-NaF PET/CT for Staging and Treating Newly Diagnosed High-Risk Prostate Cancer: A Prospective Single-Center Study. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.125.270822
Vancouver
Madsen C, Zacho HD, Fuglø D, Nielsen K, Kongsted P, Bisbjerg R, et al. 18 F-PSMA PET/CT Versus 18 F-NaF PET/CT for Staging and Treating Newly Diagnosed High-Risk Prostate Cancer: A Prospective Single-Center Study. Journal of Nuclear Medicine. 2025. doi:10.2967/jnumed.125.270822
BibTeX
@article{Madsen2025,
author = {Madsen, Claus and Zacho, Helle D and Fuglø, Dan and Nielsen, Kayalvily and Kongsted, Per and Bisbjerg, Rasmus and Pedersen, Maria and Broholm, Rikke and Haarmark, Christian and Østergren, Peter B},
title = {18 F-PSMA PET/CT Versus 18 F-NaF PET/CT for Staging and Treating Newly Diagnosed High-Risk Prostate Cancer: A Prospective Single-Center Study},
journal = {Journal of Nuclear Medicine},
year = {2025},
doi = {10.2967/jnumed.125.270822}
}
EUVIMED